Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVCR – NovoCure Limited

NovoCure Limited
NVCR
$11.27
Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $1,262,036,992.00
EPSttm : -1.61
finviz dynamic chart for NVCR
NovoCure Limited
$11.27
0.44%
$0.05

Float Short %

5.74

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

-0.05

EPS Last/This Y

0.18

EPS This/Next Y

-0.13

Price

11.27

Target Price

24.69

Analyst Recom

1.75

Performance Q

-6.63

Relative Volume

0.99

Beta

0.84

Ticker: NVCR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20NVCR14.480.150.2831315
2025-10-21NVCR14.130.150.0131804
2025-10-22NVCR13.860.150.0432323
2025-10-23NVCR13.930.1515.2732632
2025-10-24NVCR13.740.140.0632534
2025-10-27NVCR13.580.130.3332396
2025-10-28NVCR13.360.130.2232536
2025-10-29NVCR13.460.130.6132659
2025-10-30NVCR12.830.140.5633006
2025-10-31NVCR12.790.130.1132911
2025-11-03NVCR12.210.130.2732956
2025-11-04NVCR120.140.2632943
2025-11-05NVCR11.610.140.7533027
2025-11-06NVCR11.270.150.5633105
2025-11-07NVCR10.930.150.2633274
2025-11-10NVCR11.270.150.3833175
2025-11-11NVCR11.860.150.2133287
2025-11-12NVCR11.370.150.1033491
2025-11-13NVCR11.380.150.0033121
2025-11-14NVCR11.320.140.0934617
2025-11-17NVCR11.280.140.3534736
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20NVCR14.48-50.5-91.6-1.58
2025-10-21NVCR14.14-50.5-74.1-1.58
2025-10-22NVCR13.86-50.5-75.2-1.58
2025-10-23NVCR13.93-50.5-80.8-1.58
2025-10-24NVCR13.74-50.5-76.7-1.58
2025-10-27NVCR13.58-50.5-76.8-1.58
2025-10-28NVCR13.37-50.0-76.1-1.57
2025-10-29NVCR13.48-50.0-81.6-1.57
2025-10-30NVCR12.82-49.9-68.2-1.57
2025-10-31NVCR12.81-49.9-91.7-1.57
2025-11-03NVCR12.2329.5-65.0-1.43
2025-11-04NVCR11.9929.5-35.9-1.43
2025-11-05NVCR11.6129.5-33.2-1.43
2025-11-06NVCR11.2624.6-33.7-1.44
2025-11-07NVCR10.9224.6-33.5-1.44
2025-11-10NVCR11.2731.9-46.3-1.44
2025-11-11NVCR11.8631.9-50.6-1.38
2025-11-12NVCR11.3731.9-31.5-1.38
2025-11-13NVCR11.3831.9-40.0-1.38
2025-11-14NVCR11.3331.9-38.9-1.38
2025-11-17NVCR11.2731.9-38.9-1.38
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20NVCR0.51-2.215.78
2025-10-21NVCR0.51-2.215.78
2025-10-22NVCR0.51-2.215.78
2025-10-23NVCR0.51-2.215.78
2025-10-24NVCR0.51-2.215.78
2025-10-27NVCR0.51-2.015.28
2025-10-28NVCR0.51-2.015.28
2025-10-29NVCR0.51-2.015.28
2025-10-30NVCR0.51-2.015.28
2025-10-31NVCR0.51-2.015.28
2025-11-03NVCR0.51-2.045.27
2025-11-04NVCR0.51-2.045.27
2025-11-05NVCR0.51-2.045.27
2025-11-06NVCR0.51-2.045.27
2025-11-07NVCR0.51-2.045.27
2025-11-10NVCR0.51-2.065.27
2025-11-11NVCR0.51-2.065.27
2025-11-12NVCR0.51-2.065.74
2025-11-13NVCR0.51-2.065.74
2025-11-14NVCR0.51-2.065.74
2025-11-17NVCR0.51-3.655.74
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.33

Avg. EPS Est. Current Quarter

-0.42

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

0.51

Institutional Transactions

-3.65

Beta

0.84

Average Sales Estimate Current Quarter

168

Average Sales Estimate Next Quarter

168

Fair Value

Quality Score

28

Growth Score

39

Sentiment Score

32

Actual DrawDown %

95.2

Max Drawdown 5-Year %

-95.2

Target Price

24.69

P/E

Forward P/E

PEG

P/S

1.96

P/B

3.7

P/Free Cash Flow

EPS

-1.61

Average EPS Est. Cur. Y​

-1.38

EPS Next Y. (Est.)

-1.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-27.66

Relative Volume

0.99

Return on Equity vs Sector %

-79

Return on Equity vs Industry %

-70

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.2

EBIT Estimation

-38.9
NovoCure Limited
Sector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading